A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Status: Recruiting
Location: See all (25) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: f
View:
• Participants must be aged ≥ 2 to \< 11 years (Phase 2) or ≥ 2 to \< 18 years (Phase 3), at the time of signing the informed consent
• Participants must have ACH (confirmed by documented genetic testing) and open epiphyses
• Are Tanner Stage I (Phase 2) or any Tanner stage (Phase 3)
• Are ambulatory and able to stand without assistance
Locations
United States
California
UCSF Benioff Children's Hospital Oakland
RECRUITING
Oakland
Delaware
Nemours Children's Health
NOT_YET_RECRUITING
Wilmington
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING
Chicago
Maryland
Johns Hopkins Medicine
RECRUITING
Baltimore
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Pennsylvania
Children's Hospital of Philadelphia
NOT_YET_RECRUITING
Philadelphia
Texas
University of Texas Southwestern Medical Center
NOT_YET_RECRUITING
Dallas
Texas Children Hospital, Baylor College of Medicine
RECRUITING
Houston
Consano Clinical Research, LLC
RECRUITING
San Antonio
Other Locations
Australia
Murdoch Children's Research Institute
RECRUITING
Parkville
Canada
Universite de Montreal - Centre Hospitalier Universitaire Sainte-Justine
NOT_YET_RECRUITING
Montreal
Italy
Irccs Ospedale Gaslini Di Genova
NOT_YET_RECRUITING
Genova
Japan
Hokkaido University Hospital
NOT_YET_RECRUITING
Hokkaido
Osaka City General Hospital
RECRUITING
Osaka
National Center for Child Health and Development
RECRUITING
Tokyo
Poland
Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu Klinika Pediatrii i Chorob Infekcyjnych
NOT_YET_RECRUITING
Wroclaw
Republic of Korea
Seoul National University Hospital
RECRUITING
Seoul
Pusan National University Yangsan Hospital
NOT_YET_RECRUITING
Yangsan
Romania
Institutul National de Endocrinologie C.I.Parhon
NOT_YET_RECRUITING
Bucharest
Craiova Emergency Clinical County
NOT_YET_RECRUITING
Craiova
United Kingdom
University Hospitals Bristol NHS Foundation Trust - Bristol Royal Hospital for Children
RECRUITING
Bristol
Queen Elizabeth University Hospital
RECRUITING
Glasgow
Alder Hey Childrens NHS Foundation Trust
RECRUITING
Liverpool
Great Ormond Street Hospital
NOT_YET_RECRUITING
London
University NHS Foundation Trust NIHR Wellcome Trust Clinical Research Facility
RECRUITING
Manchester
Contact Information
Primary
Trial Specialist
medinfo@bmrn.com
1-800-983-4587
Backup
Study Manager
Medinfo@bmrn.com
1-800-983-4587
Time Frame
Start Date: 2026-04-20
Estimated Completion Date: 2029-09
Participants
Target number of participants: 160
Treatments
Experimental: Phase 2: Low Dose
Participants will be randomized to receive different dose levels of BMN 333
Experimental: Phase 2: Medium Dose
Participants will be randomized to receive different dose levels of BMN 333
Experimental: Phase 2: High Dose
Participants will be randomized to receive different dose levels of BMN 333
Active_comparator: Phase 2: Vosoritide
weight band dosing, Modified recombinant human C-type natriuretic peptide Vosoritide
Experimental: Phase 3: BMN 333 at selected dose after Phase 2
Active_comparator: Phase 3: Vosoritide
weight band dosing, Modified recombinant human C-type natriuretic peptide Vosoritide
Related Therapeutic Areas
Sponsors
Leads: BioMarin Pharmaceutical